Evidence map›Paper›PMID 25479096›Full record

ArticlePloS one2014

Dynein function and protein clearance changes in tumor cells induced by a Kunitz-type molecule, Amblyomin-X.

Mario T F Pacheco, Carolina M Berra, Kátia L P Morais, Juliana M Sciani, Vania G Branco, Rosemary V Bosch, Ana M Chudzinski-Tavassi

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Mario T F PachecoBiochemistry and Biophysics Laboratory, Butantan Institute, São Paulo, Brazil.
Carolina M BerraBiochemistry and Biophysics Laboratory, Butantan Institute, São Paulo, Brazil.
Kátia L P MoraisBiochemistry and Biophysics Laboratory, Butantan Institute, São Paulo, Brazil; Department of Biochemistry, Federal University of São Paulo, São Paulo, Brazil.
Juliana M ScianiBiochemistry and Biophysics Laboratory, Butantan Institute, São Paulo, Brazil.
Vania G BrancoBiochemistry and Biophysics Laboratory, Butantan Institute, São Paulo, Brazil.
Rosemary V BoschBiochemistry and Biophysics Laboratory, Butantan Institute, São Paulo, Brazil.
Ana M Chudzinski-TavassiBiochemistry and Biophysics Laboratory, Butantan Institute, São Paulo, Brazil.
Instituto Butantan · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amblyomin-X is a Kunitz-type recombinant protein identified from the transcriptome of the salivary glands of the tick Amblyomma cajennense and has anti-coagulant and antitumoral activity. The supposed primary target of this molecule is the proteasome system. Herein, we elucidated intracellular events that are triggered by Amblyomin-X treatment in an attempt to provide new insight into how this serine protease inhibitor, acting on the proteasome, could be comparable with known proteasome inhibitors. The collective results showed aggresome formation after proteasome inhibition that appeared to occur via the non-exclusive ubiquitin pathway. Additionally, Amblyomin-X increased the expression of various chains of the molecular motor dynein in tumor cells, modulated specific ubiquitin linkage signaling and inhibited autophagy activation by modulating mTOR, LC3 and AMBRA1 with probable dynein involvement. Interestingly, one possible role for dynein in the mechanism of action of Amblyomin-X was in the apoptotic response and its crosstalk with autophagy, which involved the factor Bim; however, we observed no changes in the apoptotic response related to dynein in the experiments performed. The characteristics shared among Amblyomin-X and known proteasome inhibitors included NF-κB blockage and nascent polypeptide-dependent aggresome formation. Therefore, our study describes a Kunitz-type protein that acts on the proteasome to trigger distinct intracellular events compared to classic known proteasome inhibitors that are small-cell-permeable molecules. In investigating the experiments and literature on Amblyomin-X and the known proteasome inhibitors, we also found differences in the structures of the molecules, intracellular events, dynein involvement and tumor cell type effects. These findings also reveal a possible new target for Amblyomin-X, i.e., dynein, and may serve as a tool for investigating tumor cell death associated with proteasome inhibition.

Indexed as

AnimalsApoptosisArthropod ProteinsAutophagyCell Line, TumorDyneinsHumansIxodidaeProteasome Endopeptidase ComplexProteasome InhibitorsRecombinant ProteinsSalivary Proteins and PeptidesAmblyomin-X protein, Amblyomma cajennenseArthropod ProteinsDyneinsProteasome Endopeptidase ComplexProteasome InhibitorsRecombinant ProteinsSalivary Proteins and Peptides

Identifiers

PMID25479096
PMCPMC4257547
OpenAlexW1967647168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.